Platelet derived growth factor receptor alpha. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Regorafenib CHEMBL1946170 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 43 |
| Sunitinib CHEMBL535 |
Platelet-derived growth factor receptor inhibitor Inhibitor Platelet-derived growth factor receptor alpha inhibitor Inhibitor Small molecule |
ChEMBL only | 21 |
| Famitinib CHEMBL1278146 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 11 |
| Cediranib Maleate CHEMBL2103798 |
Inhibits PDGFRA Primary target Small molecule |
Guide to Pharmacology only | 10 |
| Pazopanib CHEMBL477772 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 10 |
| Avapritinib CHEMBL4204794 |
Platelet-derived growth factor receptor alpha inhibitor Inhibitor Small molecule |
ChEMBL only | 8 |
| Nintedanib CHEMBL502835 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Quizartinib CHEMBL576982 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Midostaurin CHEMBL608533 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 5 |
| Ripretinib CHEMBL4216467 |
Platelet-derived growth factor receptor alpha inhibitor Inhibitor Small molecule |
ChEMBL only | 4 |
| Sunitinib Malate CHEMBL1567 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Masitinib CHEMBL1908391 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Seralutinib CHEMBL4650333 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Acute myeloid leukemia | 6 | Phase 3 |
| Breast cancer | 5 | Phase 3 |
| Cervical cancer | 4 | Phase 3 |
| Colorectal cancer | 4 | Phase 3 |
| Non-small cell lung carcinoma | 4 | Phase 3 |
| Age-related macular degeneration | 4 | Phase 2 |
| Fallopian tube cancer | 3 | Phase 3 |
| Gastrointestinal stromal tumor | 3 | Phase 3 |
| Hepatocellular carcinoma | 3 | Phase 3 |
| Kidney cancer | 3 | Phase 3 |
| Ovarian cancer | 3 | Phase 3 |
| Systemic mastocytosis | 3 | Phase 3 |
| Glioblastoma | 3 | Phase 2/3 |
| Acute lymphoblastic leukemia | 3 | Phase 2 |
| Adenoid cystic carcinoma | 3 | Phase 2 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
